Search Results

1 - 4 of 4 items

  • Author: Agnieszka Wierzbowska x
Clear All Modify Search


Invasive fungal disease (IFD) is one of the most serious complications of therapy in patients with immune suppression. It particularly concerns patients treated for malignant hematological diseases, immune deficiencies, or undergoing hematopoietic cell transplantation (HCT). Development of IFD can abrogate the effect of previous therapy and contributes to dismal outcome of the underlying disease. The Working Group consisting of members of the Polish Society of Hematology and Blood Transfusion, the Polish Society of Pediatric Oncology and Hematology, and the Polish Adult Leukemia Study Group has prepared recommendations for the diagnostic and therapeutic management of IFD in adults and children. This paper presents the current recommendations for patients in immune suppression treated in Polish pediatric and adult hematology and HCT centers, based on the guidelines of the European Conference on Infections in Leukaemia (ECIL) 2015–2019. Levels of diagnosis of IFD (possible, probable, and proven) and antifungal management (prophylaxis, as well as empirical and targeted therapies) are declared according to updated international criteria of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) 2019. Patients with primary diagnosis of acute lymphoblastic leukemia, acute myeloblastic leukemia, severe aplastic anemia, chronic granulomatous disease, and severe combined immunodeficiency, as well as patients after allogeneic HCT, are included in the high-risk groups for development of IFD. For these patients, antifungal prophylaxis based on azoles or micafungin is recommended. In empirical therapy, caspofungin or liposomal/lipid formulas of amphotericin B are recommended. The Working Group has discouraged the use of itraconazole in capsules and amphotericin deoxycholate. Detailed guidelines for first- and second-line targeted therapies for invasive candidiasis, aspergillosis, mucormycosis, fusariosis, and scedosporiosis, as well as the principles of the recommended dosing of antifungals, are presented in this paper.


Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP’s member, may play an exceptional role in the mechanisms of tumors’ resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell count < 20 G/L (p = 0.009, p = 0.033, and p = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo (p = 0.025 and p = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low NAIP expression, age < 60 yo, and intensive chemotherapy (p = 0.033, p < 0.001, and p < 0.001, respectively). In the intensively treated group, better OS was observed in patients with age < 60 yo, de novo AML, and a low NAIP expression (p = 0.03, p = 0.024, and p = 0.07, respectively). In multivariate analysis, longer OS was associated with age < 60 yo (p = 0.009) and de novo AML (p = 0.007). In conclusion, we suggest that NAIP might play an adverse role in response to chemotherapy.


Zakażenia należą do najczęstszych przyczyn chorobowości i śmiertelności chorych na nowotwory hematologiczne, a stosowanie szczepień ochronnych może w istotnym stopniu wpłynąć na zmniejszenie częstości ich występowania. W pracy przedstawiono przegląd danych dotyczących ryzyka zakażeń oraz skuteczności immunizacji czynnej u chorych na nowotwory hematologiczne i u pacjentów z anatomiczną lub czynnościową asplenią. Ponadto zawarto rekomendacje dla populacji polskich pacjentów opracowane przez Sekcję Zakażeń Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG) oraz Polskie Towarzystwo Hematologów i Transfuzjologów. Uwzględniono zarówno zalecenia ogólne dotyczące chorych na nowotwory, jak i szczegółowe odnoszące się do określonych nowotworów hematologicznych. Przedstawiono również propozycje poprawy organizacji szczepień u chorych na nowotwory hematologiczne w Polsce.